专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004041867A3 CAMELIDAE ANTIBODIES AGAINST IMMINOGLOBULIN E AND USE THEREOF FOR THE TREATMENT OF ALLERGIC DISORDERS 审中-公开
标题翻译： CAMELIDAE抗体免疫球蛋白E及其用于治疗过敏性疾病的药物
公开(公告)号：WO2004041867A3
公开(公告)日：2004-08-12
申请号：PCT/BE0300190
申请日：2003-11-07
申请人： ABLYNX NV , SILENCE KAREN , VAECK MARK , VAN BERGEN EN HENEGOUWEN PAUL
发明人： SILENCE KAREN , VAECK MARK , VAN BERGEN EN HENEGOUWEN PAUL
IPC分类号： A61K39/395 , A61P11/06 , A61P19/02 , A61P31/06 , A61P31/16 , A61P35/00 , A61P37/06 , C07K16/10 , C07K16/12 , C07K16/18 , C07K16/24 , C07K16/28 , C07K16/30 , C07K16/36 , C07K16/40 , C07K16/42 , C07K16/46 , C12N15/13 , G01N33/577
CPC分类号： C07K16/468 , A61K2039/505 , C07K16/18 , C07K16/241 , C07K16/249 , C07K16/2863 , C07K16/2875 , C07K16/36 , C07K16/40 , C07K16/42 , C07K16/4291 , C07K2317/22 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/565 , C07K2317/569 , C07K2317/626 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , C07K2319/00
摘要： The invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention furthe relates to anti-IgE therapeutic molecules.
摘要翻译：本发明涉及通过使用衍生自骆驼科抗体的VHH多肽，适用于口服，舌下，局部，静脉内，皮下，经鼻，阴道，直肠或吸入施用蛋白质治疗分子的方法，以避免失活。本发明还涉及所述治疗分子。本发明还提供了一种将治疗分子递送至细胞内部的方法。本发明涉及抗IgE治疗分子。

2. 发明申请

WO2004041865A3 STABILIZED SINGLE DOMAIN ANTIBODIES 审中-公开
标题翻译：稳定的单一抗体
公开(公告)号：WO2004041865A3
公开(公告)日：2004-07-15
申请号：PCT/BE0300193
申请日：2003-11-07
申请人： ABLYNX NV , SILENCE KAREN , LAUWEREYS MARC , DREIER TORSTEN
发明人： SILENCE KAREN , LAUWEREYS MARC , DREIER TORSTEN
IPC分类号： A61K39/395 , A61P11/06 , A61P19/02 , A61P31/06 , A61P31/16 , A61P35/00 , A61P37/06 , C07K16/10 , C07K16/12 , C07K16/18 , C07K16/24 , C07K16/28 , C07K16/30 , C07K16/36 , C07K16/40 , C07K16/42 , C07K16/46 , C12N15/13 , G01N33/577
CPC分类号： C07K16/2863 , A61K2039/505 , C07K16/18 , C07K16/241 , C07K16/249 , C07K16/2875 , C07K16/36 , C07K16/40 , C07K16/4291 , C07K2317/22 , C07K2317/24 , C07K2317/31 , C07K2317/565 , C07K2317/569 , C07K2317/62 , C07K2317/626 , C07K2317/76 , C07K2317/77 , C07K2319/00 , C07K2319/31
摘要： The present invention relates to heterospecific polypeptide constructs comprising at least one single domain antibody directed against a therapeutic and/or diagnostic target and at least one single domain antibody directed against a serum protein, said construct having a prolonged lifetime in biological circulatory systems. The invention further relates to methods for stabilising VHHs in biological circulatory systems.
摘要翻译：本发明涉及包含针对治疗和/或诊断靶标的至少一个单结构域抗体和针对血清蛋白质的至少一个单域抗体的异种多肽构建体，所述构建体在生物循环系统中具有延长的使用寿命。本发明还涉及在生物循环系统中稳定VHH的方法。

3. 发明申请

WO2004062551A3 RECOMBINANT VHH SINGLE DOMAIN ANTIBODY FROM CAMELIDAE AGAINST VON WILLEBRAND FACTOR (vWF) OR AGAINST COLLAGEN 审中-公开
标题翻译：来自CAMELIDAE的重组VHH单抗抗体对Von WILLEBRAND因子（vWF）或对COLLAGEN
公开(公告)号：WO2004062551A3
公开(公告)日：2004-09-02
申请号：PCT/BE2004000002
申请日：2004-01-09
申请人： ABLYNX NV , SILENCE KAREN
发明人： SILENCE KAREN
IPC分类号： A61K20060101 , A61K38/49 , A61K39/395 , A61M31/00 , A61P7/02 , A61P11/06 , A61P19/02 , A61P31/06 , A61P31/16 , A61P35/00 , A61P37/06 , C07K16/18 , C07K16/36 , C07K16/42 , C12N15/13
CPC分类号： C07K16/18 , A61K38/166 , A61K38/49 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61L29/085 , A61L29/16 , A61L31/10 , A61L31/16 , A61L2300/256 , A61L2300/42 , A61L2420/02 , C07K16/2896 , C07K16/36 , C07K2317/22 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/569 , G01N33/68 , G01N33/6893 , G01N33/86 , G01N2333/47 , G01N2333/755 , G01N2500/02 , G01N2500/04 , G01N2800/222 , A61K2300/00
摘要： The present invention relates to polypeptides comprising at least one single domain antibody directed against vWF, vWF A1 domain, A1 domain of activated vWF, vWF A3 domain, gpIb and/or collagen, for the treatment for conditions which require a modulation of platelet-mediated aggregation. A further aspect of the invention is methods of production of said polypeptides, methods to coat devices with such polypeptides used in medical procedures (e.g. PCTA, stenting) and kits for the diagnosis of diseases related to platelet-mediated aggregation.
摘要翻译：本发明涉及包含针对vWF，vWF A1结构域，活化的vWF的A1结构域，vWF A3结构域，gpIb和/或胶原的至少一种单域抗体的多肽，用于治疗需要调节血小板介导的病症聚合。本发明的另一方面是生产所述多肽的方法，用于医疗程序中使用的这种多肽（例如PCTA，支架置入）和用于诊断与血小板介导的聚集有关的疾病的试剂盒的装置的方法。

4. 发明申请

WO2004041862A3 SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST TUMOUR NECROSIS FACTOR-ALPHA AND USES THEREFOR 审中-公开
标题翻译：针对肿瘤坏死因子ALPHA的单抗抗体及其用途
公开(公告)号：WO2004041862A3
公开(公告)日：2004-06-24
申请号：PCT/BE0300192
申请日：2003-11-07
申请人： ABLYNX NV , SILENCE KAREN , LAUWEREYS MARC , DE HAARD HANS
发明人： SILENCE KAREN , LAUWEREYS MARC , DE HAARD HANS
IPC分类号： A61K39/395 , A61P11/06 , A61P19/02 , A61P31/06 , A61P31/16 , A61P35/00 , A61P37/06 , C07K16/10 , C07K16/12 , C07K16/18 , C07K16/24 , C07K16/28 , C07K16/30 , C07K16/36 , C07K16/40 , C07K16/42 , C07K16/46 , C12N15/13 , G01N33/577
CPC分类号： C07K16/2863 , A61K2039/505 , C07K16/18 , C07K16/241 , C07K16/249 , C07K16/2875 , C07K16/36 , C07K16/40 , C07K16/4291 , C07K2317/22 , C07K2317/24 , C07K2317/31 , C07K2317/565 , C07K2317/569 , C07K2317/62 , C07K2317/626 , C07K2317/76 , C07K2317/77 , C07K2319/00 , C07K2319/31
摘要： The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Tumor Necrosis Factor-alpha. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides.
摘要翻译：本发明涉及衍生自针对肿瘤坏死因子-α的单结构域重链抗体的多肽。它还涉及骆驼科VHHs的单结构域抗体。它还涉及施用所述多肽的方法。

5. 发明申请

WO2006074947A3 METHODS AND ASSAYS FOR DISTINGUISHING BETWEEN DIFFERENT FORMS OF DISEASES AND DISORDERS CHARACTERIZED BY THROMBOCYTOPENIA AND/OR BY SPONTANEOUS INTERACTION BETWEEN VON WILLEBRAND FACTOR (vWF) AND PLATELETS 审中-公开
标题翻译：用于鉴别不同形式的由血细胞素和/或血管性血友病因子（vWF）与血小板之间的自发相互作用表征的疾病和病症的方法和测定
公开(公告)号：WO2006074947A3
公开(公告)日：2006-09-14
申请号：PCT/EP2006000273
申请日：2006-01-13
申请人： ABLYNX NV , UMC UTRECHT HOLDING BV , DE GROOT PHILIP G , FIJNHEER ROB , LENTING PETER J , SILENCE KAREN
发明人： DE GROOT PHILIP G , FIJNHEER ROB , LENTING PETER J , SILENCE KAREN
IPC分类号： G01N33/68 , G01N33/86
CPC分类号： G01N33/86 , G01N33/6893 , G01N2333/755 , G01N2800/222
摘要： The invention relates to a method for distinguishing between different states or forms of diseases and disorders characterized by thrombocytopenia and/or by spontaneous interaction between Von Willebrand Factor (vWF) and platelets, and/or to predict the progression of such a disease or disorder, said method comprising the steps of providing at least one biological sample obtained from a patient suffering from, or suspected to suffer from, at least one disease or disorder characterized by thrombocytopenia and/or by spontaneous interaction between Von Willebrand Factor (vWF) and platelets and of determining the amount of activated vWF in said biological sample, in which the amount of activated vWF in the sample is representative for the different states or forms of the disease or disorder. The invention further relates to a kit-of-parts for determining the amount of activated vWF in a sample and to the use of an antibody that is capable of specifically binding activated vWF in the presence of non-activated vWF; of a part or fragment of an antibody.
摘要翻译：本发明涉及用于区分血小板减少症和/或血管性血友病因子（vWF）与血小板之间的自发相互作用和/或预测这种疾病或病症的发展的不同状态或形式的疾病和病症的方法，所述方法包括以下步骤：提供从患有或疑似患有以血小板减少症和/或血管性血友病因子（vWF）与血小板之间的自发相互作用为特征的至少一种疾病或病症的患者获得的至少一种生物样品，和确定所述生物样品中活化的vWF的量，其中样品中活化的vWF的量代表疾病或紊乱的不同状态或形式。本发明进一步涉及用于确定样品中活化的vWF的量的试剂盒和使用能够在非活化的vWF存在下特异性结合活化的vWF的抗体; 的抗体的部分或片段。

6. 发明申请

WO2009115614A3 VON WILLEBRAND FACTOR SPECIFIC BINDERS AND METHODS OF USE THEREFOR 审中-公开
标题翻译： VON WILLEBRAND因子特异性粘合剂及其使用方法
公开(公告)号：WO2009115614A3
公开(公告)日：2010-04-08
申请号：PCT/EP2009053385
申请日：2009-03-23
申请人： ABLYNX NV , HOLZ JOSEFIN-BEATE , SILENCE KAREN , ULRICHTS HANS , DE BUCK STEFAN , BARTUNEK JOZEF , KLAMROTH ROBERT
发明人： HOLZ JOSEFIN-BEATE , SILENCE KAREN , ULRICHTS HANS , DE BUCK STEFAN , BARTUNEK JOZEF , KLAMROTH ROBERT
IPC分类号： A61P7/02 , A61K31/616 , A61K31/727
CPC分类号： A61K39/3955 , A61K31/00 , A61K31/4365 , A61K31/616 , A61K31/727 , A61K38/17 , G01N33/86 , G01N2800/324 , G01N2800/52
摘要： The invention provides new uses for specific binders to the Al domain of the von Willebrand Factor (vWF), in particular the use in patients with stable angina undergoing elective percutaneous coronary intervention. Furthermore, dosing schedules and use of suitable assays such as RIPA and RICO in the particular disease settings are provided.
摘要翻译：本发明提供了对von Willebrand因子（vWF）的Al结构域的特异性结合物的新用途，特别是在经历选择性经皮冠状动脉介入治疗的稳定型心绞痛患者中的用途。此外，提供给药方案和在特定疾病设置中使用合适的测定例如RIPA和RICO。

7. 发明申请

WO2006122825A2 IMPROVED NANOBODIES FOR THE TREATMENT OF AGGREGATION-MEDIATED DISORDERS 审中-公开
标题翻译：用于治疗聚集介导的疾病的改善的纳米比亚
公开(公告)号：WO2006122825A2
公开(公告)日：2006-11-23
申请号：PCT/EP2006004773
申请日：2006-05-19
申请人： ABLYNX NV , SILENCE KAREN
发明人： SILENCE KAREN
CPC分类号： C07K16/36 , A61K38/36 , A61K2039/505 , C07K2317/22 , C07K2317/24 , C07K2317/569 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to improved Nanobodies against von Willebrand Factor (vWF), as well as to polypeptides comprising or essentially consisting of one or more of such Nanobodies. The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host cells expressing or capable of expressing such Nanobodies or polypeptides; to compositions comprising such Nanobodies, polypeptides, nucleic acids or host cells; and to uses of such Nanobodies, such polypeptides, such nucleic acids, such host cells or such compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes.
摘要翻译：本发明涉及抗血管性血友病因子（vWF）的改进的纳米抗体，以及包含或基本上由一种或多种这样的纳米抗体组成的多肽。本发明还涉及编码这种纳米抗体和多肽的核酸; 制备这种纳米抗体和多肽的方法; 宿主表达或能够表达这种纳米抗体或多肽的细胞; 包含这样的纳米抗体，多肽，核酸或宿主细胞的组合物; 以及这样的纳米抗体，这种多肽，这种核酸，这种宿主细胞或这种组合物的用途，特别是用于预防，治疗或诊断目的，例如预防，治疗或诊断目的。

8. 发明申请

WO2006122825A9 IMPROVED NANOBODIES FOR THE TREATMENT OF AGGREGATION-MEDIATED DISORDERS 审中-公开
标题翻译：改进的纳米粒子用于治疗聚集介导的疾病
公开(公告)号：WO2006122825A9
公开(公告)日：2007-03-29
申请号：PCT/EP2006004773
申请日：2006-05-19
申请人： ABLYNX NV , SILENCE KAREN
发明人： SILENCE KAREN
CPC分类号： C07K16/36 , A61K38/36 , A61K2039/505 , C07K2317/22 , C07K2317/24 , C07K2317/569 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to improved Nanobodies against von Willebrand Factor (vWF), as well as to polypeptides comprising or essentially consisting of one or more of such Nanobodies. The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host cells expressing or capable of expressing such Nanobodies or polypeptides; to compositions comprising such Nanobodies, polypeptides, nucleic acids or host cells; and to uses of such Nanobodies, such polypeptides, such nucleic acids, such host cells or such compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes.
摘要翻译：本发明涉及抗血管性血友病因子（vWF）的改进的纳米抗体，以及包含或基本上由一种或多种这样的纳米抗体组成的多肽。本发明还涉及编码这种纳米抗体和多肽的核酸; 制备这种纳米抗体和多肽的方法; 宿主表达或能够表达这种纳米抗体或多肽的细胞; 涉及包含这样的纳米抗体，多肽，核酸或宿主细胞的组合物; 以及这样的纳米抗体，这种多肽，这种核酸，这种宿主细胞或这种组合物的用途，特别是用于预防，治疗或诊断目的，例如预防，治疗或诊断目的。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式